Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. A Multicenter, Open-label, Phase II Trial

NCT03708003 is registered in ClinicalTrials.gov with Swiss Cancer Institute as lead sponsor.

NCT NCT03708003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03708003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. A Multicenter, Open-label, Phase II Trial
Lead sponsor
Swiss Cancer Institute
Phase
Phase 2
Overall status
Terminated
Start date
March 11, 2019
Completion date
November 30, 2025
Enrollment
30 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, leukemia, relapsed/refractory chronic lymphocytic leukemia